Sinobiomed’s New U.S. Leadership Seeks Licensing Deals, Strategic Investment From Global Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Chinese firm’s board brings in a slate of U.S. execs to engineer a turnaround after Sinobiomed's valuation drops from $400 million to $10 million.
You may also be interested in...
Venture Capitalists Freeze Funding For Some U.S. Start-ups, But Could Channel More Investment Into China Health Care
BEIJING - While the Western world's financial maelstrom is already choking off funding for some biotech start-ups in the U.S., it could have the opposite effect in China, and trigger the flow of more capital into promising Chinese healthcare outfits, according to a partner in a half-billion-dollar venture capital firm
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.
New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus In Troubled Financial Seas
GlaxoSmithKline provides leading-edge vaccine technology and equipment, along with an injection of cash totaling almost $30 million, while Neptunus contributes its production facilities and access to the Chinese market.